Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

ACCESSWIRE

2024-11-01

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:	Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call
Date:	Thursday, November 14, 2024
Time:	10:00am ET
Conference Call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast:	Webcast \| Third Quarter 2024 Financial Results and Business Update Conference Call

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers¹. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/

Contacts:

Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

SOURCE: Biofrontera Inc.

View the original press release on accesswire.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2480839940"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480839940\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480839940?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002","is_english":true,"pubTime":"2024-11-01 23:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480839940","market":"us","top_or_hot":-1,"title":"Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024","media":"ACCESSWIRE","content":"<html><body><p><strong>WOBURN, MA / ACCESSWIRE / November 1, 2024 / <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\")</strong>, a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.</p>\n<p><strong>Conference Call and Webcast Information</strong></p>\n<figure>\n<table>\n<tbody>\n<tr>\n<td><p><span><strong>Event:</strong></span></p></td>\n<td><p><span><strong>Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Date:</strong></span></p></td>\n<td><p><span><strong>Thursday, November 14, 2024</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Time:</strong></span></p></td>\n<td><p><span><strong>10:00am ET</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Conference Call:</strong></span></p></td>\n<td><p><span><strong>1-877-877-1275 (U.S.)</strong></span></p><p><span><strong>1-412-858-5202 (international)</strong></span></p></td>\n</tr>\n<tr>\n<td><p><span><strong>Webcast:</strong></span></p></td>\n<td><p><span><strong>Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call</strong></span></p></td>\n</tr>\n</tbody>\n</table>\n</figure>\n<p><strong>About Biofrontera Inc.</strong></p>\n<p>Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers<sup>1</sup>. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.</p>\n<p><strong>1 - </strong><strong>https://www.skincancer.org/skin-cancer-information/actinic-keratosis/</strong></p>\n<p><strong>Contacts:</strong></p>\n<p>Investor Relations<br/>Andrew Barwicki<br/>1-516-662-9461<br/>ir@bfri.com<br/><br/><br/></p>\n<p><strong>SOURCE: </strong>Biofrontera Inc.</p>\n<br/>\n<br/>View the original \npress release on accesswire.com\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 23:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biofrontera-inc-report-third-quarter-155500583.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\"), a biopharmaceutical company specializing in the development and commercialization of PDT, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biofrontera-inc-report-third-quarter-155500583.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BFRI","symbol_name":"Biofrontera Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-report-third-quarter-155500583.html","article_id":"2480839940","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480839940","pubTimestamp":1730476500,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc.  , a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call. Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to exte","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BFRI":"Biofrontera Inc","BK4007":"制药","BFRIW":"Biofrontera Inc Warrant"},"translate_title":"Biofrontera Inc.将于2024年11月13日报告第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFRI":1,"BFRIW":0.9},"content_text":"WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.\nConference Call and Webcast Information\n\n\n\n\nEvent:\nBiofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call\n\n\nDate:\nThursday, November 14, 2024\n\n\nTime:\n10:00am ET\n\n\nConference Call:\n1-877-877-1275 (U.S.)1-412-858-5202 (international)\n\n\nWebcast:\nWebcast | Third Quarter 2024 Financial Results and Business Update Conference Call\n\n\n\n\nAbout Biofrontera Inc.\nBiofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.\n1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/\nContacts:\nInvestor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com\nSOURCE: Biofrontera Inc.\n\nView the original \npress release on accesswire.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}